TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO, May 5,...
Hence then, the article about tremfya guselkumab positioned to become the first and only il 23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( TREMFYA® (guselkumab) positioned to become the first and only IL-23 inhibitor to offer subcutaneous induction in ulcerative colitis as demonstrated in new data through 24 weeks )
Also on site :
- Carson Kressley Just Mic-Dropped Vicki Gunvalson’s ‘RHOC’ Motor Boating Outfit and the Internet Can’t Stop Screaming
- Brad Bird’s ‘Ray Gunn,’ ‘Toy Story 5’ and Roger Deakins Lead View Conference Lineup as AI Debate Takes Center Stage
- Andrea Bocelli and Ludacris Are Ringing in 2027 at the Same Tropical Destination, and It’s Not Where You’d Expect